Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
NEW YORK, April 01, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Horizon Pharma plc (NASDAQ:HZNP) securities between March 13, 2014 and February 26, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/horizon-pharma. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Horizon’s Prescriptions Made Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs; (ii) sales revenues from drugs sold through Horizon’s PME program were unsustainable at these inflated price levels; and (iii) Horizon’s use of its PME program left the Company subject to increased regulatory risks.
On February 29, 2016, Horizon disclosed in its 2015 annual report that the Company received a subpoena in November 2015 from the Office of the U.S. Attorney for the Southern District of New York for documents and information related to the Company’s patient assistance programs and other aspects of Horizon’s sales and marketing activities.
If you suffered a loss in Horizon you have until May 9, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/horizon-pharma.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigation involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
